This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Walgreens Tumbles on Costly Global Deal (Update 1)

Stocks in this article: WAGESRXCVSRADKKR

Updated to include CEO comments and additional analyst reactions.

NEW YORK ( TheStreet) -- Amid a contract standoff with competitor Express Scripts (ESRX) and sales losses to CVS Caremark (CVS) , Walgreens (WAG), the largest drugstore chain in the U.S., is hitting back after taking a 45% stake in European pharmacy giant Alliance Boots for $6.7 billion, in a cash and stock deal.

For Walgreens, the deal could transform the company into an international pharmacy powerhouse with a top presence in the U.S. and Europe, while giving it a growth and M&A strategy that differs from competitors Express Scripts and CVS Caremark who have scaled their U.S. presence through large deals in recent years.

However, analyst reactions and Walgreens tumbling shares signal that the company has to prove now is the time to invest in an international and European growth push, and that it can offset prospective market share losses in the fast-consolidating U.S. pharmacy industry.

With Alliance Boots, Walgreens will become one of the world's top drug store and pharmacies with over 11,000 stores in 12 countries, primarily in North America and Europe. For both companies, the deal fills a big strategic need; however, it comes at a big cost.

Walgreens will pay $4 billion in cash and $2.7 billion in its stock for a 45% stake in Alliance Boots and will have the option to buy a remaining 55% stake in Alliance Boots for $9.5 billion in coming years. That prospective $16.2 billion takeover valuation also comes with roughly $11 billion in Alliance Boots debt after its 2007 private equity buyout led by private equity giant KKR (KKR).

Already, Walgreens has lined up $3.5 billion in bridge financing from Goldman Sachs and Bank of America Merrill Lynch to pay for the first leg of the deal.

Faced with a standoff on a $5 billion drug prescriptions contract with Express Scripts, and key customer losses to CVS Caremark, Tuesday's stake acquisition gives Walgreens a growth plan to counter quarterly sales losses. Meanwhile, Alliance Boots has found an entry into the U.S. after its chairman and part owner Stefano Pessina said that he would look for a "transformational" deal to turn the company from a European powerhouse into an international player.

The question is whether the timing of Walgreens bold international push and the strategy can add to the company's earnings, which may be hit by its Express Scripts standoff and customer losses.

"It is not surprising to see Walgreens pursue a substantial investment to mitigate the risk of lost Medco Health Solutions business and its limited opportunity to recover Express Scripts business," wrote Bank of America Merrill Lynch analyst Robert Willoughby, in a note to clients. Willoughby re-iterated an underperform rating on Walgreens and a $26 a share price target, citing continued U.S. market share losses to Express Scripts and CVS Caremark.

Walgreens said that the deal may add up to 27 cents to its diluted earnings per share after the deal closes, on an expected $150 million in annual cost savings and up to $1 billion in synergies through 2016.

In spite of a tough economy, Walgreens chief executive Gregory Wasson said the deal was done at "the right time," stressing that Alliance Boots generates the bulk of its revenue from stable European countries and that pharmacies historically perform well in a tough economy. Synergies will come from procurement and the introduction of Alliance Boots beauty brands to Walgreens stores, Wasson added.

"The synergy numbers are very real," says GAMCO Investors analyst Jeff Jonas, highlighting verticals like drug procurement and Boots' beauty products. Still, Jonas calls the deal "defensive" and says that, as a result, Walgreens paid a full price of roughly 10-to-11 times Alliance Boots' expected earnings.

"There is certainly no discount for Europe," says Jonas of the deal, adding that upside will hinge on continued double digit growth at Alliance Boots. "It's really execution at this point... and the global economy." Jonas adds that an alternative would have been for Walgreens to take a profit hit on a settlement with Express Scripts and use its cash to boost share buybacks.

Guggenheim Securities analyst John Heinbockel questions the timing of the EU push and cautions that the deal may not offset a prospective earnings loss if Express Scripts takes its existing Medco contracts, after their merger.

" We always thought that such expansion efforts would occur further down the line, be relatively modest in scale, and be initially centered on the faster growing Latin American markets," writes Heinbockel.

Walgreen also said it would increase its quarterly dividend to 27.5 cents per share from 22.5 cents.

In Tuesday trading, Walgreen shares tumbled nearly 6% to $30.09, near 52-week lows hit in pre-market trading. The Deerfield, Ill- based company's shares are off nearly 10% in 2012, underperforming double digit 2012 stock gains by Express Scripts and CVS Caremark.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,677.90 +216.58 1.32%
S&P 500 1,950.82 +23.71 1.23%
NASDAQ 4,452.7920 +69.9450 1.60%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs